Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...

Beta Bionics recently brought its iLet bionic pancreas to market in 2023 and completed an IPO to become a publicly-traded ...

(NEXSTAR) – New cases of a dangerous, drug-resistant fungus have been identified in at least two states’ hospital systems. Candida auris, also called C. auris, was first identified in the U.S ...

Acute pancreatitis is a serious condition that causes the pancreas to become inflamed. It develops suddenly and can cause severe pain in the upper abdomen, often spreading to your back or left ...